# Plan — R vs SAS: When $50K Licences Are Hard to Justify

## A. Frontmatter

| Field | Value |
|---|---|
| `title` | R vs SAS: When $50K Licences Are Hard to Justify — An Honest Comparison |
| `slug` | R-vs-SAS |
| `description` | SAS still rules pharma and banking, but R is closing the gap fast. Compare licence costs, 2026 job demand, statistical depth, and ecosystem maturity. |
| `keywords` | R vs SAS, SAS vs R, R or SAS, SAS alternative, R for pharma, SAS to R migration, R FDA submissions, R SAS cost comparison |
| `auto_link_terms` | R vs SAS\|SAS vs R\|R or SAS\|SAS alternative |
| `auto_link_case_sensitive` | false |
| `mathjax` | false |
| `webr` | true |
| `date` | 2026-04-13 |
| `curriculum_id` | CMP3 |
| `post_type` | FR |
| `fr_parent` | Is-R-Worth-Learning-in-2026.html |

## B. Breadcrumb (auto-generated — do NOT write into markdown)

Home > Learn R > R vs Other Tools > R vs SAS: When $50K Licences Are Hard to Justify — An Honest Comparison

## C. Outline

### Lead paragraph

SAS still wins where a 40-year regulatory paper trail matters (pharma, large banks, government). R wins almost everywhere else — and the gap is closing faster in the places SAS used to own. This page puts the cost, capability, job-market, and compliance arguments on one screen so you can make the call for your own team without the vendor spin.

### First H2 opening plan (≤80 words)

For two decades the "R or SAS" debate was mostly anecdote. You can settle the usage side of it with public data: the TIOBE index, SAS's own 10-K financials, job-board listings, and CRAN/SAS module counts. Let's pull those numbers into a small data frame, plot them, and see the picture you actually pay the licence for.

### Core H2 sections

**H2 1: Who actually uses R and SAS in 2026?** (entry point)
- Theory: SAS started as a 1976 statistics package for IBM mainframes. R started as an open-source clone of S in 1993. Today SAS Institute is a private company with ~$3B revenue; R is a CRAN-hosted language with 21,000+ packages.
- Code block 1 (PAYOFF): Build a tibble of 4 public usage indices (TIOBE rank, Kaggle survey %, Indeed listings share, Stack Overflow dev survey %), plot as horizontal bar chart with ggplot2. This is the payoff — reader sees the gap instantly.
- Code block 2: Quick `dplyr` summary — compute R-advantage ratio per index.
- Diagram: none here.
- Callout: KEY INSIGHT — "SAS sits where switching is hardest (regulated industries), not where it's technically best."
- Inline exercise: reader modifies the tibble to add a 5th index and re-plots.

**H2 2: How big is the licence-cost gap, really?**
- Theory: SAS has no public price list; enterprise deals are bespoke. But industry reports consistently put per-user licences at $8K–$15K/yr and full enterprise deployments (SAS Viya, multiple modules) at $500K–$2M/yr. R is GPL-2 — base is free forever; Posit Team (paid server) is optional.
- Code block: data frame with licence-cost ranges for 5 deployment sizes (1 analyst, 10, 50, 250, 1000); plot stacked bars showing annual R-total-cost-of-ownership vs SAS. R TCO dominated by salaries + Posit Team; SAS TCO dominated by licence.
- Callout: NOTE — these are list prices. Negotiated SAS deals can be 30-60% lower, especially in academia and pharma.
- Inline exercise: recompute TCO for a 25-user team using the reader's own numbers.

**H2 3: Is R actually accepted by the FDA?**
- Theory: This is the single question that keeps SAS alive in pharma. The FDA's official guidance (Statistical Software Clarifying Statement, 2015 + reaffirmed 2022) says "FDA does not require use of any specific software." Roche submitted a breast-cancer trial end-to-end in R. Novo Nordisk ran a dual R+SAS submission pilot. The R Consortium's Submissions Working Group maintains validated reference submissions on GitHub.
- Code block: small tibble of public R-based FDA/EMA/PMDA submissions (company, year, indication, dual-programmed?). Filter and display with `dplyr`.
- Callout: WARNING — "FDA accepts R, but your internal SOP still has to accept it. Validation, not regulation, is usually the real bottleneck."
- Inline exercise: filter the submissions table to only dual-programmed trials.

**H2 4: Which tool has more statistical capability today?**
- Theory: SAS ships ~300 PROCs covering classical statistics, with the depth polished over 40 years. R has ~21,000 CRAN packages plus Bioconductor (2,200+ bio packages). New methods (e.g., modern Bayesian, causal inference, geospatial) land on CRAN within weeks of publication; SAS adds them on a yearly release cadence, if at all.
- Code block: tibble comparing capability areas (classical stats, Bayesian, ML, deep learning, spatial, bioinformatics, time series, text). Each row scored 1–5 for R and SAS. Plot as side-by-side ggplot bars.
- Callout: TIP — "For anything invented after 2015, check CRAN first. You'll almost always find it there before SAS adds a PROC."
- Inline exercise: compute the capability gap (R score − SAS score) per area.

**H2 5: What does the 2026 job market say?**
- Theory: LinkedIn/Indeed/Glassdoor show R jobs concentrated in pharma, biotech, academic research, and public health — roughly flat YoY. SAS jobs concentrated in pharma (again), banking, insurance, and government — declining ~8%/yr for 5 years. Salaries comparable in pharma; R higher in tech and consulting.
- Code block: tibble of job listings share by industry, plot as ggplot faceted bars (R vs SAS per industry).
- Callout: KEY INSIGHT — "The SAS job market is not dying; it's consolidating into a smaller number of very stable, very well-paid roles in 2-3 industries."
- Inline exercise: add a new industry row (e.g., tech) and re-plot.

**H2 6: When should you actually pick each tool?**
- Theory: Decision framework. Pick SAS when: regulated submissions, existing SAS investment, team skill lock-in, PROC-based statisticians. Pick R when: new projects, open-source ecosystem access, modern methods, cost constraints, reproducible research, academic pipeline.
- Code block: a decision-table tibble with 8 scenarios × recommendation × reason. Print with `knitr::kable()` for clean output.
- Diagram: decision-tree flowchart (mermaid) — embedded as image.
- Callout: TIP — "You don't have to pick one forever. Dual-programming (R primary + SAS QC) is the most common path for pharma teams already running SAS."
- Inline exercise: add a new scenario row for "Geospatial epidemiology" and pick R with justification.

### Tail sections

**`## Practice Exercises`** (2 capstones — FR post, keep it light)

1. *Exercise 1 (medium):* Build a 5-year TCO comparison for a 25-analyst team assuming 3% annual salary inflation and negotiated SAS discount of 40%. Print the break-even point.
2. *Exercise 2 (hard):* Given a tibble of (industry, R_listings, SAS_listings), compute the R-advantage ratio per industry and return only industries where R beats SAS by more than 2×.

**`## Putting It All Together`** — Worked example: a hypothetical mid-size biotech (50 analysts, moving from SAS to R). Compute 5-year savings, estimate migration cost, identify which 30% of SAS code stays (validated legacy PROCs for regulatory), and plot the ROI curve.

**`## Summary`** — Takeaway bullets + one-screen decision table.

**`## References`** — 7 sources:
1. FDA Statistical Software Clarifying Statement (2015, reaffirmed 2022)
2. R Consortium R Submissions Working Group — github.com/RConsortium/submissions-wg
3. Roche Pilot Submission (PHUSE 2020 paper)
4. Novo Nordisk R submission pilot (PHUSE 2022)
5. TIOBE Index for SAS / R
6. SAS Institute 2024 Annual Report (revenue, headcount)
7. Posit "What is Posit Team?" pricing page

**`## Continue Learning`** — 3 related posts:
- Is R Worth Learning in 2026? (parent FR hub)
- R vs Python for Data Science: Stop Debating and Read the Actual Data
- R vs SPSS: Why 40% of SPSS Users Are Moving to R

## D. Diagram list

| # | Filename | Figure | Caption | Placed in H2 |
|---|---|---|---|---|
| 1 | `R-vs-SAS-decision-tree.webp` | Figure 1 | When to pick R, SAS, or both — a practical decision tree for 2026 teams. | When should you actually pick each tool? |
| 2 | `R-vs-SAS-ecosystem-compare.webp` | Figure 2 | Side-by-side ecosystem sizes — CRAN packages vs SAS PROCs in 2026. | Which tool has more statistical capability today? |

No overview mindmap. No figures above the first code block.

## E. Code block master list

| # | Demonstrates | Libs | Vars introduced | Vars used |
|---|---|---|---|---|
| 1 | Load libs + plot 4-index usage comparison | ggplot2, dplyr, tibble, scales | `usage_df` | — |
| 2 | R-advantage ratio per index | — | `ratio_df` | `usage_df` |
| 3 | Inline exercise starter: add 5th index | — | `ex_usage` | `usage_df` |
| 4 | Licence cost TCO data frame + stacked bar | — | `tco_df` | — |
| 5 | Inline exercise: recompute for 25-user team | — | `ex_tco` | — |
| 6 | FDA R-based submissions tibble | — | `submissions_df` | — |
| 7 | Inline exercise: dual-programmed only | — | `ex_dual` | `submissions_df` |
| 8 | Capability matrix R vs SAS + grouped bars | — | `cap_df` | — |
| 9 | Inline exercise: gap per area | — | `ex_gap` | `cap_df` |
| 10 | 2026 job listings share tibble + faceted bars | — | `jobs_df` | — |
| 11 | Inline exercise: add tech industry | — | `ex_jobs` | `jobs_df` |
| 12 | Decision-table tibble + knitr::kable | knitr | `decision_df` | — |
| 13 | Inline exercise: add geospatial scenario | — | `ex_decision` | `decision_df` |
| 14 | Capstone 1: 5-year TCO with inflation + discount | — | `capstone1` | — |
| 15 | Capstone 2: R-advantage filter | — | `capstone2` | — |
| 16 | Putting it all together: biotech migration ROI | — | `migration_df`, `roi_plot` | — |

Rules check: libs only on block 1 (and `knitr` on block 12 — needed for `kable`, not in base); every "Vars used" appears in a prior block's "Vars introduced".

## F. Estimated counts

- H2 sections: 11 (6 core + 5 tail)
- Code blocks: ~16
- Diagrams: 2
- Callouts: ~7 (KEY×2, TIP×2, WARNING×1, NOTE×2)
- Target word count: ~3,200
